Obstructive sleep apnea (OSA) is associated with various negative health consequences including increased risk of heart disease, hypertension and daytime sleepiness causing road accidents. The economic burden of OSA is rising as almost 1 billion people worldwide are estimated to have OSA. The current diagnostic metric, however, relates poorly to these symptoms and comorbidities. It merely measures the frequency of breathing cessations without assessing OSA severity in any other physiologically relevant way. Furthermore, the clinical methods for analyzing PSG signals are outdated, expensive and laborious. Due to this, the majority of OSA patients remain without diagnosis or have an inaccurate diagnosis leading to sub-optimal treatment. Thus, it is evident that more personalized diagnostics are required including predictive and preventive health care and patient participation. The SLEEP REVOLUTION aims to develop machine learning techniques to better estimate OSA severity and treatment needs to improve health outcomes and quality of life. These techniques are implemented to high-end wearables developed in this project to alleviate the costs and increase the availability of PSGs. Finally, we aim to design a digital platform that functions as a bridge between researchers, patients and healthcare professionals. We will achieve these ambitious goals throughout extensive collaboration between sleep specialists, computer scientists and industry partners. The collaboration network consists of over 30 sleep centers working together to provide the needed retrospective data (over 10.000 sleep studies). The multi-center prospective trials involve experts and end-users to assess and validate the new SLEEP REVOLUTION diagnostic algorithms, wearables and platforms. With the commitment of the European Sleep Research Society and Assembly of National Sleep Societies (over 8000 members), we have the unique possibility to create new standardized guidelines for sleep medicine in the EU.

The Gravitate-Health mission is to equip and empower citizens with digital information tools that make them confident, active, and responsive in their patient journey, specifically encouraging safe use of medicines for better health outcomes and quality of life. It is our vision that engagement of citizens in their own health can only be achieved with access to actionable, understandable, relevant, reliable and evidence-based information that meets their specific needs, health context, and literacy level. This project's ambition is to provide a key piece to advance this vision: the Gravitate Lens (G-lens), which focuses (but does not conceal or filter) approved electronic product information (ePI) content, and offers a route for patients to access trustworthy, up-to-date information that better meet their individual needs. Gravitate-Health is an integrated digital health information project. The principle objective is to demonstrate how use of an integrated, digital, user-centric health information solution with two-way communication could enable tangible improvements in availability and understanding of health information from a set of trusted sources, starting with regulator-approved medicinal product information (e.g. package leaflet content) and EHR-IPS (International Patient Summary). The secondary objectives are to demonstrate that the improved availability and understanding of health information from trusted sources translate to higher levels of adherence to treatment, safer use of medication (Pharmacovigilance), better health outcomes and quality of life, and to develop new and deeper insights into how use of available health information can be optimized to act as effective risk minimization measures. The project allows for efficient and timely development of the G-lens, provides testing grounds for new services and an evaluation framework to test the efficiency, efficacy and safety of Gravitate-Health services. Our main outputs will be an open source digital platform supporting G-lens functionally, demonstrated in a number of testing scenarios, and a White Paper with recommendations on realistic strategies to strengthen access, understanding and future use of digital services like ePIs as a tool for Risk Minimization. The Gravitate-Health is a public – private partnership with 45 members from Europe and the US, co-led by University of Oslo (coordinator) and Pfizer (industry lead), funded by the Innovative Medicines Initiative (IMI) – a joint undertaking of the European Commission, the European Federation of Pharmaceutical Industries and Associations (EFPIA), IMI Associated Partners.